2
Kenya Medical Research Institute (KEMRI) in collaboration with Merck Sharp & Dohme LLC (MSD) and
International Clinical Research Centre (ICRC) at the University of Washington (UW) is conducting a Phase
3, randomized, double-blind, interventional study evaluating the efficacy of Oral MK-8527 as a monthly
PrEP regimen compared to the standard daily FTC/TDF regimen for the prevention of HIV-1 infection in
cisgender women aged 16 to 30 years with a follow up of approximately 27 months, assessing the safety,
effectiveness, and adherence of a once-monthly oral PrEP option.
